- RecruitingPHASE3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This study looks at a new combination of drugs, adagrasib, pembrolizumab, and chemotherapy, for people with a specific type of advanced non-small cell lung cancer (NSCLC) that hasn't been treated before and has a KRAS G12C gene change.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
For: Advanced Non-Small Cell Lung Cancer · Metastatic Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - Active not recruitingPHASE2
Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status
This study is looking at a new drug called adagrasib for people with a specific type of advanced lung cancer. It focuses on patients who are older (70+) or have poorer health, to see how well the drug works in shrinking their cancer.
For: NSCLC Stage IV · KRAS P.G12CBelgium · France · Ireland - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
This study is looking into a new treatment, BMS-986488, for advanced cancers. Researchers want to see if it's safe, tolerable, and effective, either on its own or with other medicines, for people whose cancer has spread or can't be removed with surgery.
For: Advanced Malignant TumorsUnited States · Australia · Canada